Wednesday, July 23, 2008

Phase II Patient Recruitment for TPI ASM8 Completed

TOPIGEN Pharmaceuticals, has announced that patient recruitment and enrollment for the Phase II safety and efficacy study for TPI ASM8 drug has been successfully completed. It is an inhaled, anti-inflammatory drug for treatment of moderate to severe asthmas. Chief Development Officer for TOPIGEN, Mark Parry-Billings, had this to say about completion at this stage:

"The completion of patient recruitment in this Phase II trial is on schedule, and represents a significant clinical achievement for TOPIGEN. We look forward to completing the study and reporting on data at the end of this year.”

Billings also had this to add:

“There is a significant clinical need for improved medications to treat this patient group, particularly those patients who do not respond adequately to conventional medication. TPI ASM8 has the potential to provide an effective and well-tolerated approach to improve asthma control in these patients, and has the added advantage over other pipeline products of being delivered simply by inhalation."

No comments:

Post a Comment